The GLP-1 Telehealth Informed Consent Process: What Good Providers Require

Informed consent is the legal and ethical foundation of every medical treatment. For GLP-1 telehealth, where the speed and convenience of digital enrollment can sometimes compress clinical processes, the quality of informed consent reveals how seriously a platform takes its obligation to educate and protect patients.

What Informed Consent Must Cover for GLP-1 Treatment

A clinically adequate informed consent for GLP-1 medication should address these elements at minimum:

The nature of the treatment. The patient should understand what GLP-1 medications do (mechanism of action in plain language), how they're administered (injection technique and frequency), and what the treatment timeline looks like (titration schedule and expected duration of therapy).

Expected benefits. Realistic weight loss expectations based on clinical trial data — not marketing promises. The average weight loss is 15-25% of body weight with full adherence, but individual results vary significantly. Patients should understand that results are not guaranteed.

Known risks and side effects. All common side effects (GI effects, injection site reactions), serious risks (pancreatitis, gallbladder events, thyroid concerns, allergic reactions), and the boxed warning about medullary thyroid carcinoma should be disclosed. This disclosure should be specific, not a generic "all medications have risks" statement.

Alternative treatments. The patient should be informed of alternatives including lifestyle modification, other weight loss medications (metformin, naltrexone-bupropion, phentermine), and bariatric surgery. Informed consent requires that the patient understand their options, not just the option the platform sells.

Compounding disclosure. If the medication is compounded, the patient must understand that it is not FDA-approved as a finished product, that it is prepared by a compounding pharmacy under state regulation, and what that means for quality assurance. This is a legal requirement under most state pharmacy laws.

Red Flags in the Consent Process

These indicators suggest the consent process is inadequate:

• Consent is buried in terms of service. Medical informed consent should be a separate, clearly identified document — not paragraph 47 of a general terms of service agreement.
• No mention of compounding status. If you're receiving compounded medication and the consent form doesn't address compounding, the platform is withholding material information.
• No opportunity to ask questions. Clicking "I agree" without access to a provider for questions doesn't meet the standard.
• Risks are minimized or omitted. Consent forms that emphasize benefits while glossing over risks ("mild temporary side effects") are not providing balanced information.
• No consent for specific procedures. Some platforms require lab work or other assessments. Consent should cover these as well.

Your Rights in the Consent Process

As a patient, you have the right to:

• Take time to review. You should not be pressured to sign consent immediately during a consultation. Taking 24-48 hours to review is reasonable.
• Ask questions. Any question about your treatment, its risks, alternatives, or the provider's qualifications is valid and should be answered.
• Receive a copy. You should receive a copy of your signed consent form for your records.
• Withdraw consent. Informed consent is ongoing. You can withdraw consent and discontinue treatment at any time.